ATH-1105 is an orally delivered, positive modulator of the neurotrophic HGF system that is currently in a Phase 1 clinical trial with completion expected by year end 2024 and commencement of dosing of ALS patients expected in 2025  Company announces cost containment measures in alignment with focus on advancing ATH-1105 BOTHELL, Wash., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal he ...

Company Overview - Athira Pharma, Inc. (ATHA) shares fell 72.2% in after-hours trading on September 3 due to disappointing results from the phase II/III LIFT-AD study for its candidate fosgonimeton in treating mild-to-moderate Alzheimer's disease (AD) [1] - The LIFT-AD study did not meet its primary endpoint, the Global Statistical Test (GST), which combines cognition and function measures [1] - Key secondary endpoints related to cognition, function, plasma biomarkers of neurodegeneration, protein pathology, and neuroinflammation were also not met [1] Study Results - In pre-specified subgroups of moderate AD patients or APOE4 gene carriers, cognition and function showed improvement or stabilization with fosgonimeton compared to placebo [2] - Prespecified biomarker analyses indicated that cognition and function, key measures of GST, favored treatment with fosgonimeton over placebo [2] Alzheimer's Disease Market - Biogen and Eisai's Leqembi received FDA approval for early AD treatment in July 2023, with expectations for blockbuster sales due to significant unmet needs in the AD market [3] - Eli Lilly's Kisunla (donanemab) was approved by the FDA in July 2024, making it the second drug available for early symptomatic AD [4] - Other companies, including Prothena Corporation, AC Immune, and Cassava Sciences, are also developing therapies for Alzheimer's disease [4] Stock Performance - Athira has seen a 16.4% increase in shares year-to-date, outperforming the industry growth of 0.6% [1] - Athira currently holds a Zacks Rank 2 (Buy) [5] - Illumina, Inc. (ILMN) is highlighted as a top-ranked stock in the biotech sector with a Zacks Rank 1 (Strong Buy) [5]

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Group 1 - Athira Pharma, Inc. (ATHA) is currently ranked 2 (Buy) in the Zacks Rank system, indicating strong potential for outperforming the market in the next one to three months [1] - The Zacks Consensus Estimate for ATHA's full-year earnings has increased by 8.2% over the past quarter, reflecting improved analyst sentiment and earnings outlook [2] - Year-to-date, ATHA has gained approximately 28%, significantly outperforming the average gain of 11.1% for stocks in the Medical group [2] Group 2 - Athira Pharma, Inc. is part of the Medical - Biomedical and Genetics industry, which consists of 497 companies and is currently ranked 84 in the Zacks Industry Rank [3] - The Medical - Biomedical and Genetics industry has seen an average gain of 1.9% this year, indicating that ATHA is performing better than its industry peers [3] - HCA Healthcare, another notable stock in the Medical sector, has returned 41.5% year-to-date and is ranked 1 (Strong Buy) in the Zacks Rank [2][3]

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | --- | |----------------------------------------------------------------------------|----------------------------------------------------------------------------------------|---------------- ...

Exhibit 99.1 Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates Topline data from completed Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mildto-moderate Alzheimer's disease targeted for September 2024 Phase 2/3 LIFT-AD data to be presented in an oral presentation at CTAD in October 2024 Phase 1 clinical trial of ATH-1105 underway for the potential treatment of amyotrophic lateral sclerosis (ALS) BOTHELL, Wash., August 1, 2024 – Athi ...

Topline data from completed Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer’s disease targeted for September 2024 Phase 2/3 LIFT-AD data to be presented in an oral presentation at CTAD in October 2024 Phase 1 clinical trial of ATH-1105 underway for the potential treatment of amyotrophic lateral sclerosis (ALS) BOTHELL, Wash., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused ...

Fosgonimeton mitigated amyloid-β-induced toxicity, lowered pTau levels and reduced disruption of protein clearance mechanisms that may contribute to pTau pathology Fosgonimeton treatment, alone and in combination with lecanemab, protected cultures of primary neurons from the toxic effects of amyloid-β BOTHELL, Wash., July 31, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow n ...